51
|
Tribius S, Meyer MS, Pflug C, Hanken H, Busch CJ, Krüll A, Petersen C, Bergelt C. Socioeconomic status and quality of life in patients with locally advanced head and neck cancer. Strahlenther Onkol 2018; 194:737-749. [PMID: 29736758 DOI: 10.1007/s00066-018-1305-3] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Accepted: 04/10/2018] [Indexed: 12/14/2022]
Abstract
PURPOSE Socioeconomic aspects play an important role in health care. Patients with locally advanced head and neck cancer (LAHNC) experience detrimental effects on their quality of life (QoL). This prospective study examines QoL differences between patients with different socioeconomic status (SES) after intensity-modulated radiation therapy (IMRT). PATIENTS AND METHODS In all, 161 patients were questioned at the end of IMRT and at 12 and 24 months follow-up using the questionnaires of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 and QLQ-HN35. Patients' QoL 2 years after IMRT was compared to a population reference sample and QoL of patients from lower, middle, and higher social class 2 years after IMRT was analyzed by ANCOVA using baseline QoL (end of radiation treatment) as a covariate. RESULTS Patients with high SES report worse QoL at the end of IMRT in the domains global health status (-15.2; p = 0.005), role function (-23.8; p = 0.002), and social function (-19.4; p = 0.023) compared to patients with middle and low SES. QoL improved during the first 12 and 24 months. However, 2 years after IMRT, middle and low SES patients report lower QoL in the domains global health status, physical function, and role function, and report a higher general (fatigue, pain, dyspnea) and head and neck cancer-specific symptom burden (pain, swallowing, senses, speech, social eating, opening mouth, and felt ill) than patients with high SES. CONCLUSION After IMRT for LAHNC, patients with high SES report worse QoL compared to patients with middle or low SES. There is a marked improvement within the first 24 months in many domains. However, the magnitude of improvement in patients with middle or low SES is significantly smaller compared to patients with high SES.
Collapse
|
52
|
Klement R, Hoerner-Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble M, Eich H, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl K, Klass N, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt T, Wittig A, Guckenberger M. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiother Oncol 2018; 127:246-252. [DOI: 10.1016/j.radonc.2018.02.016] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 02/14/2018] [Accepted: 02/15/2018] [Indexed: 12/25/2022]
|
53
|
Köcher S, Volquardsen J, Nordquist L, Lange T, Schlomm T, Beyer B, Petersen C, Rothkamm K, Mansour W. EP-2301: ERG overexpression in PCa drives a switch to the alt-EJ which render cells radiosensitive to PARPi. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32610-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
54
|
Hörner-Rieber J, Abbasi-Senger N, Blanck O, Boda-Heggemann J, Duma M, Eble M, Eich H, Flentje M, Gerum S, Haas P, Henkenberens C, Imhoff D, Kahl H, Klass N, Krempien R, Lohaus F, Petersen C, Sackerer I, Schrade E, Uhlmann L, Wittig A, Guckenberger M. PV-0043: Histology as predictor for outcome following SBRT in NSCLC patients with lung oligo-metastases. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30353-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
55
|
Petersen C, Bertram N, Schliffke M, Amelung VE, Göhl M, Binder S, Bergen S. DIMINI – Activation of health literacy in persons with an increased risk of type 2 diabetes mellitus by coaching at general practitioners: evaluation concept and study design. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641955] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
56
|
Oing C, Dyshlovoy S, Honecker F, Nordquist L, Rothkamm K, Bokemeyer C, Petersen C, Mansour W. EP-1618: Monoubiquitinylated histone H2B as a potential target in treatment resistant germ cell tumors. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31927-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
57
|
Rieckmann T, Busch C, Hintelmann K, Berenz T, Kriegs M, Münscher A, Petersen C, Rothkamm K. OC-0490: Targeting PARP1 and the intra-S/G2 checkpoints for highly effective radiosensitization of HPV+ HNSCC. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30800-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
58
|
Guckenberger M, Klement R, Rieber J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble M, Eich H, Flentje M, Gerum S, Haas P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass N, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt T, Wittig A. PV-0044: Repeat sbrt for pulmonary oligo-metastases. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30354-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
59
|
Cassidy L, Petersen C, Treitz C, Dierking K, Schulenburg H, Leippe M, Tholey A. The Caenorhabditis elegans Proteome Response to Naturally Associated Microbiome Members of the Genus Ochrobactrum. Proteomics 2018. [PMID: 29513928 DOI: 10.1002/pmic.201700426] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The nematode Caenorhabditis elegans interacts with a variety of bacteria as it feeds on microbes, and a number of these both associate and persist within the worm's intestine. Host-microbe interactions in C. elegans have been analyzed primarily at the transcriptome level with the host response often been monitored after challenge with pathogens. We assessed the proteome of C. elegans after growth on bacteria capable of colonizing its gut, via a comparative analysis of the nematode exposed to two naturally associated Ochrobactrum spp. (MYb71, MYb237) versus C. elegans grown on Escherichia coli OP50. A total of 4677 C. elegans proteins were identified, 3941 quantified. Significant alterations in protein abundances were observed for 122 proteins, 48 higher and 74 lower in abundance. We observed an increase in abundance of proteins potentially regulated via host signaling pathways, in addition to proteins involved in processing of foreign entities (e.g., lipase, proteases, glutathione metabolism). Decreased in abundance were proteins involved in both degradation and biosynthesis of amino acids, and enzymes associated with the degradation of peptidoglycan (lysozymes). The protein level differences between C. elegans grown on native microbiome members compared to the laboratory food bacterium may help to identify molecular processes involved in host-microbe interactions.
Collapse
|
60
|
Madadi-Sanjani O, Petersen C. Aufruf zur Teilnahme an der Evaluation des Stuhlkartenscreenings. Monatsschr Kinderheilkd 2018. [DOI: 10.1007/s00112-018-0481-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
61
|
Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Guckenberger M, Hildebrandt G, Klement RJ, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Habermehl D. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 2018; 18:283. [PMID: 29534687 PMCID: PMC5851117 DOI: 10.1186/s12885-018-4191-2] [Citation(s) in RCA: 93] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 03/06/2018] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND The intent of this pooled analysis as part of the German society for radiation oncology (DEGRO) stereotactic body radiotherapy (SBRT) initiative was to analyze the patterns of care of SBRT for liver oligometastases and to derive factors influencing treated metastases control and overall survival in a large patient cohort. METHODS From 17 German and Swiss centers, data on all patients treated for liver oligometastases with SBRT since its introduction in 1997 has been collected and entered into a centralized database. In addition to patient and tumor characteristics, data on immobilization, image guidance and motion management as well as dose prescription and fractionation has been gathered. Besides dose response and survival statistics, time trends of the aforementioned variables have been investigated. RESULTS In total, 474 patients with 623 liver oligometastases (median 1 lesion/patient; range 1–4) have been collected from 1997 until 2015. Predominant histologies were colorectal cancer (n = 213 pts.; 300 lesions) and breast cancer (n = 57; 81 lesions). All centers employed an SBRT specific setup. Initially, stereotactic coordinates and CT simulation were used for treatment set-up (55%), but eventually were replaced by CBCT guidance (28%) or more recently robotic tracking (17%). High variance in fraction (fx) number (median 1 fx; range 1–13) and dose per fraction (median: 18.5 Gy; range 3–37.5 Gy) was observed, although median BED remained consistently high after an initial learning curve. Median follow-up time was 15 months; median overall survival after SBRT was 24 months. One- and 2-year treated metastases control rate of treated lesions was 77% and 64%; if maximum isocenter biological equivalent dose (BED) was greater than 150 Gy EQD2Gy, it increased to 83% and 70%, respectively. Besides radiation dose colorectal and breast histology and motion management methods were associated with improved treated metastases control. CONCLUSION After an initial learning curve with regards to total cumulative doses, consistently high biologically effective doses have been employed translating into high local tumor control at 1 and 2 years. The true impact of histology and motion management method on treated metastases control deserve deeper analysis. Overall survival is mainly influenced by histology and metastatic tumor burden.
Collapse
|
62
|
Rorsman I, Petersen C, Nilsson P. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial. Acta Neurol Scand 2018; 137:117-124. [PMID: 28901547 DOI: 10.1111/ane.12833] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/22/2017] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Cognitive impairment is common in multiple sclerosis (MS) and can have serious impact on social and occupational functioning. Natalizumab reduces relapse rates, magnetic resonance imaging (MRI) lesions, and progression of disability. Previous studies on cognitive functioning have not based inclusion on cognitive performance criteria. The aim of the present study was to determine any potential natalizumab-related cognitive effects on MS patients performing below normal limits on neuropsychological testing. MATERIALS AND METHODS Patients starting natalizumab (n = 21) and a quasi-control group of stable MS patients (n = 13) on first line disease modifying treatment were included following neuropsychological assessment demonstrating subnormal cognitive performance. Assessment, using ten cognitive variables, was repeated after 12 months. Symptoms of fatigue, anxiety and depression were also examined. Raw scores on the cognitive tests were transformed into Z-scores based on published age-corrected normative data. RESULTS Between-group analyses on difference Z-scores (baseline - follow-up) yielded significant results on Paced Auditory Serial Addition Test-2 (PASAT-2) (P = .008), with the natalizumab group showing larger improvement than quasi control patients. On PASAT-2, 28,5% from the natalizumab group demonstrated >1 SD improvement, indicative of clinically meaningful change, compared with none in the quasi control group. Patients receiving natalizumab showed within-group improvements on six of the ten cognitive variables. There were no group differences in symptoms of fatigue, anxiety or depression. CONCLUSIONS The results demonstrate improvement in information processing speed following 12-months of natalizumab treatment. The results are interpreted as reflection of anti-inflammatory properties of natalizumab rather than retest- or long-term restorative effects.
Collapse
|
63
|
Schneider HC, Petersen C, Povstyanko A, Fedoseev A, Makarov O. Repeatability of irradiation damage and of recovery by post-irradiation annealing of EUROFER base steels. FUSION ENGINEERING AND DESIGN 2017. [DOI: 10.1016/j.fusengdes.2017.04.066] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
64
|
Aimo A, Vergaro G, Castiglione V, Barison A, Pasanisi E, Petersen C, Chubuchny V, Giannoni A, Poletti R, Maffei S, Januzzi J, Passino C, Emdin M. P444Effect of sex on reverse remodelling in chronic systolic heart failure. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
65
|
Chubuchnyy V, Pasanisi E, Petersen C, Giannoni A, Barison A, Taddei C, Poggianti E, Valleggi A, Mirizzi G, Emdin M. P5848Different features of cardiac involvement in patients with AL vs. TTR amyloidosis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
66
|
Klement R, Guckenberger M, Alheid H, Allgaeuer M, Becker G, Blanck O, Boda-Hegemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. OC-0523: SBRT for oligo-metastatic liver disease–effect of chemotherapy and histology on local tumor control. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30963-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
67
|
Petersen C, Pyne D, Portus M, Cordy J, Dawson B. Analysis of performance at the 2007 Cricket World Cup. INT J PERF ANAL SPOR 2017. [DOI: 10.1080/24748668.2008.11868417] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
68
|
Petersen C, Pyne D, Portus M, Dawson B. Analysis of Twenty/20 Cricket performance during the 2008 Indian Premier League. INT J PERF ANAL SPOR 2017. [DOI: 10.1080/24748668.2008.11868448] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
69
|
Petersen C, Pyne D, Portus M, Dawson B. Quantifying positional movement patterns in Twenty20 cricket. INT J PERF ANAL SPOR 2017. [DOI: 10.1080/24748668.2009.11868474] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
70
|
Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 2017; 123:227-233. [PMID: 28274491 DOI: 10.1016/j.radonc.2017.01.013] [Citation(s) in RCA: 78] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Revised: 01/02/2017] [Accepted: 01/21/2017] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Stereotactic body radiation therapy (SBRT) is applied in the oligometastatic setting to treat liver metastases. However, factors influencing tumor control probability (TCP) other than radiation dose have not been thoroughly investigated. Here we set out to investigate such factors with a focus on the influence of histology and chemotherapy prior to SBRT using a large multi-center database from the German Society of Radiation Oncology. METHODS 452 SBRT treatments in 363 patients were analyzed after collection of patient, tumor and treatment data in a multi-center database. Histology was considered through random effects in semi-parametric and parametric frailty models. Dose prescriptions were parametrized by conversion to the maximum biologically effective dose using alpha/beta of 10Gy (BEDmax). RESULTS After adjusting for histology, BEDmax was the strongest predictor of TCP. Larger PTV volumes, chemotherapy prior to SBRT and simple motion management techniques predicted significantly lower TCP. The model predicted a BED of 209±67Gy10 necessary for 90% TCP at 2years with no prior chemotherapy, but 286±78Gy10 when chemotherapy had been given. Breast cancer metastases were significantly more responsive to SBRT compared to other histologies with 90% TCP at 2years achievable with BEDmax of 157±80Gy10 or 80±62Gy10 with and without prior chemotherapy, respectively. CONCLUSIONS Besides dose, histology and pretreatment chemotherapy were important factors influencing local TCP in this large cohort of liver metastases. After adjusting for prior chemotherapy, our data add to the emerging evidence that breast cancer metastases do respond better to hypofractionated SBRT compared to other histologies.
Collapse
|
71
|
Tanadini-Lang S, Rieber J, Filippi AR, Fode MM, Streblow J, Adebahr S, Andratschke N, Blanck O, Boda-Heggemann J, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Petersen C, Schrade E, Wendt TG, Wittig A, Høyer M, Ricardi U, Sterzing F, Guckenberger M. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol 2017; 123:182-188. [PMID: 28169042 DOI: 10.1016/j.radonc.2017.01.003] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2016] [Revised: 12/28/2016] [Accepted: 01/03/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Radical local treatment of pulmonary metastases is practiced with increasing frequency due to acknowledgment and better understanding of oligo-metastatic disease. This study aimed to develop a nomogram predicting overall survival (OS) after stereotactic body radiotherapy (SBRT) for pulmonary metastases. PATIENTS AND METHODS A multi-institutional database of 670 patients treated with SBRT for pulmonary metastases was used as training cohort. Cox regression analysis with bidirectional variable elimination was performed to identify factors to be included into the nomogram model to predict 2-year OS. The calibration rate of the nomogram was assessed by plotting the actual Kaplan-Meier 2-year OS against the nomogram predicted survival. The nomogram was externally validated using two separate monocentric databases of 145 and 92 patients treated with SBRT for pulmonary metastases. RESULTS The median follow up of the trainings cohort was 14.3months, the 2-year and 5-year OS was 52.6% and 23.7%, respectively. Karnofsky performance index, type of the primary tumor, control of the primary tumor, maximum diameter of the largest treated metastasis and number of metastases (1 versus >1) were significant prognostic factors in the Cox model (all p<0.05). The calculated concordance-index for the nomogram was 0.73 (concordance indexes of all prognostic factors between 0.54 and 0.6). Based on the nomogram the training cohort was divided into 4 groups and 2-year OS ranged between 24.2% and 76.1% (predicted OS between 30.2% and 78.4%). The nomogram discriminated between risk groups in the two validation cohorts (concordance index 0.68 and 0.67). CONCLUSIONS A nomogram for prediction of OS after SBRT for pulmonary metastases was generated and externally validated. This tool might be helpful for interdisciplinary discussion and evaluation of local and systemic treatment options in the oligo-metastatic setting. KEY MESSAGE A nomogram for prediction of overall survival after stereotactic body radiotherapy (SBRT) for pulmonary metastases was developed and externally validated. This tool might be helpful for interdisciplinary discussion and evaluation of local and systemic treatment options in the oligo-metastatic setting.
Collapse
|
72
|
Kebed K, Moustafa TAMER, Conte R, Doering C, Van Grootel RWJ, Badacz R, Nemes A, Uejima T, Oehman J, Ceponiene I, Fabiani I, Garcia Martin A, Nishikawa H, Jurko AJR, Pasanisi E, Zagatina A, Stoian M, Monteagudo Ruiz JM, Lazaro Mendes AS, Ruiz Fernandez D, Chong A, Park YH, Mizariene V, Hlubocka Z, Ring L, Kruse E, Addetia K, Ciszek B, Thykattil M, Guile B, Lang RM, Mor-Avi V, Mahfouz RAGAB, Elzayat AHMED, Goda MOHAMD, Gad MARWA, Sansone F, Napoli F, Tonacci A, Raciti M, Landi P, Grande A, Ait-Ali L, Sveric K, Richter U, Strasser RH, Wunderlich C, Menting ME, Mcghie JS, Strachinaru M, Vletter WB, Geleijnse ML, Roos-Hesselink JW, Van Den Bosch AE, Kablak-Ziembicka A, Urbanczyk-Zawadzka M, Banys RP, Musialek P, Pieniazek P, Mleczko S, Zmudka K, Przewlocki T, Marton I, Domsik P, Kalapos A, Posfai E, Modok S, Borbenyi Z, Forster T, Takahashi L, Nishikawa H, Semba H, Sawada H, Yamashita T, Jurkevicius R, Petkeviciene J, Gustiene O, Tamuleviciute-Prasciene E, Motiejunaite J, Slapikas R, Pugliese NR, La Carrubba S, Antonini Canterin F, Colonna P, Caso P, Benedetto F, Citro R, Carerj S, Di Bello V, Moya Mur JL, Lazaro Rivera C, Rincon Diaz LM, Miguelena Hycka J, Garcia Lledo A, Jimenez Nacher JJ, Fernandez-Golfin C, Rodriguez-Roda J, Zamorano JL, Uejima T, Takahashi L, Semba H, Sawada H, Yamashita T, Jurko A, Jurko T, Mistinova-Polakova J, Sbrana F, Petersen C, Bigazzi F, Dal Pino B, Coceani M, Ripoli A, Pianelli M, Luciani R, Sampietro T, Zhuravskaya N, Vareldzhyan Y, Kamenskikh M, Shmatov D, Zamfir D, Vijiiac A, Pitic D, Tamasescu G, Onciul S, Onut R, Stefan C, Dorobantu M, Gonzalez-Gomez A, Izurieta C, Fernandez-Golfin C, Marco A, Alonso Salinas GL, Hinojar Baydes R, Garcia Martin A, Casas Rojo E, Zamorano JL, Ferreira AR, Moura Ferreira J, Leite L, Oliveira AP, Ribeiro N, Barbosa AJ, Mata Martins R, Ramos D, Pego M, Gamaza Chulian S, Diaz Retamino E, Camacho Freire S, Gutierrez Barrios A, Oneto Otero J, Bansal M, Grewal HK, Kasliwal RR, Wahi S, Lee SH, Lee DS, Hwang JM, Kim JS, Kim JH, Chun KJ, Bieseviciene M, Verseckaite R, Jonkaitiene R, Janenaite J, Jurkevicius R, Dostalova G, Hlubocky J, Novotny R, Vondracek V, Lindner J, Linhart A, Preston NK. Poster Session 1The imaging examination and quality assessmentP185Why did the normal values of the left and right atrial volumes increase in the recent chamber quantification guidelines update?P186Atrial electromechanical delay, Left Atrial mechanical functions and longitudinal left ventricular strain in pre-diabetic patientsP187A web-based platform for e-training in echocardiographyP188Righ atrial size as a marker of success in electrical cardioversion in patients with persistent atrial fibrillationP189Echocardiographic assessment of left atrial dimensions and function in a healthy populationP190Impact of carotid artery revascularization on the cognitive and functional outcome and cerebral flow on TCD and brain MRI in patients with symptomatic carotid artery stenosis: a preliminary reportP191Aortic elasticity is impaired in hypereosinophilic syndromeP192Disturbed intracardiac flow transit prognosticates early decompensation in dilated cardiomyopathyP193Ultrasound guided treatment in acute heart failureP194Determinants of impaired global longitudinal function in middle-aged subjects free of cardiovascular diseaseP195Left ventricular remodeling in asymptomatic heart failure: classification and prognostic evaluationP196Restricted displacement of lateral right ventricular wall: a physiopathological explanation of geometrical and functional cardiac changes after cardiac surgeryP197A novel method to image intracardiac flow stagnation for the risk stratification for thrombosisP198Magnetic resonance imaging of anomalous origin of the left coronary artery from the pulmonary artery in children older than 4 monthsP199Coronary flow reserve is improved by LDL apheresis in patients with familial hypercholesterolemia and chronic ischemic heart diseaseP200 High velocities in the proximal part of the coronary arteries during routine echocardiography can predict nearest prognosisP201Recovery potential of the right ventricular function in the setting of a first STEMI treated by primary PCI: an echocardiographic studyP202Severe aortic stenosis patients with preserved ejection fraction according to flow and gradient classification: prevalence and outcomesP203Is basal left ventricular ejection time able to predict the severity of aortic stenosis in patients with depressed ejection fraction?P204Acceleration time in aortic stenosis: a new echocardiographic diagnostic parameterP205Application of novel Doppler indices of stenosis severity in the assessment of rheumatic mitral stenosis beyond conventional valve area and transvalvular gradientsP206Comparison of conventional echo score in patients with symptomatic rheumatic mitral stenosis: transesophageal echocardiography versus transthoracic echocardiographyP207Speckle-tracking echocardiography in evaluation early left ventricular systolic dysfunction in asymptomatic aortic regurgitation patients with good left ventricular ejection fractionP208Expansible aortic ring annuloplasty: mid-term results of aortic valve repairP209Papillary muscle dysfunction: insights into mitral valve prolapse using speckle tracking imaging. Eur Heart J Cardiovasc Imaging 2016. [DOI: 10.1093/ehjci/jew236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
73
|
Struve N, Brend T, Ott L, Petersen C, Rothkamm K, Short SC, Kriegs M. P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.111] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
74
|
Petersen C, Püschner F, Göhl M, Amelung V, Schütt M. Diabetes Präventionsprogramm aha! – Erste Erfolge werden sichtbar! DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1584113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
75
|
Petersen C. Book Review: Emerging Zoonoses and Pathogens of Public Health Concern. Vet Pathol 2016. [DOI: 10.1354/vp.42-6-860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|